Drs. Danzig and Vakharia review new AAO 2025 data on high-dose aflibercept, early corticosteroid implants, and emerging TKI inserts for RVO, DME, and wet AMD. These therapies aim to maintain vision while reducing injection burden through extended dosing and promising safety profiles.
